Thompson Siegel & Walmsley LLC decreased its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 19.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,986 shares of the pharmacy operator's stock after selling 23,277 shares during the quarter. Thompson Siegel & Walmsley LLC's holdings in CVS Health were worth $6,036,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Cypress Capital Group lifted its position in shares of CVS Health by 5.1% in the 3rd quarter. Cypress Capital Group now owns 6,654 shares of the pharmacy operator's stock worth $418,000 after purchasing an additional 320 shares during the period. Landscape Capital Management L.L.C. lifted its holdings in CVS Health by 45.4% during the third quarter. Landscape Capital Management L.L.C. now owns 75,524 shares of the pharmacy operator's stock worth $4,749,000 after buying an additional 23,594 shares during the period. Intech Investment Management LLC boosted its position in CVS Health by 70.5% during the 3rd quarter. Intech Investment Management LLC now owns 96,520 shares of the pharmacy operator's stock valued at $6,069,000 after acquiring an additional 39,919 shares in the last quarter. Payden & Rygel purchased a new position in shares of CVS Health in the 3rd quarter valued at $6,282,000. Finally, Pzena Investment Management LLC lifted its stake in shares of CVS Health by 1.5% during the 3rd quarter. Pzena Investment Management LLC now owns 13,135,308 shares of the pharmacy operator's stock worth $825,948,000 after purchasing an additional 198,920 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.
Analyst Ratings Changes
CVS has been the subject of several analyst reports. StockNews.com lowered shares of CVS Health from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. Royal Bank of Canada lowered their target price on shares of CVS Health from $68.00 to $58.00 and set an "outperform" rating for the company in a research note on Friday, November 15th. Deutsche Bank Aktiengesellschaft reduced their price target on CVS Health from $64.00 to $63.00 and set a "hold" rating on the stock in a research report on Friday, August 9th. UBS Group raised their price objective on CVS Health from $60.00 to $62.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Finally, TD Cowen raised CVS Health from a "hold" rating to a "buy" rating and upped their target price for the company from $59.00 to $85.00 in a research report on Friday, October 4th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $72.28.
View Our Latest Stock Analysis on CVS
CVS Health Trading Up 1.6 %
Shares of NYSE CVS traded up $0.91 during midday trading on Friday, reaching $58.01. 10,428,506 shares of the stock were exchanged, compared to its average volume of 11,356,283. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $73.00 billion, a P/E ratio of 14.72, a P/E/G ratio of 0.94 and a beta of 0.55. The stock has a 50 day moving average price of $59.21 and a 200-day moving average price of $58.59. CVS Health Co. has a 52-week low of $52.71 and a 52-week high of $83.25.
CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The business had revenue of $95.43 billion for the quarter, compared to analysts' expectations of $92.72 billion. During the same period last year, the company earned $2.21 earnings per share. The company's quarterly revenue was up 6.3% on a year-over-year basis. Equities research analysts expect that CVS Health Co. will post 5.43 earnings per share for the current fiscal year.
CVS Health Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were paid a $0.665 dividend. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.59%. CVS Health's dividend payout ratio (DPR) is currently 67.51%.
About CVS Health
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
